Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Neuroimage Clin ; 23: 101822, 2019.
Article in English | MEDLINE | ID: mdl-31003069

ABSTRACT

OBJECTIVE: We aimed to understand the impact of dopamine receptor D4 (DRD4) polymorphisms on neurodegeneration in patients with dementia. We hypothesized that DRD4dampened-variants with reduced functional potency would be associated with greater atrophy in regions with higher receptor density. Given that DRD4 is concentrated in anterior regions of the limbic and cortical forebrain we anticipated genotype effects in patients with a more rostral pattern of neurodegeneration. METHODS: 337 subjects, including healthy controls, patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD) underwent genotyping, structural MRI, and cognitive/behavioral testing. We conducted whole-brain voxel-based morphometry to examine the relationship between DRD4 genotypes and brain atrophy patterns within and across groups. General linear modeling was used to evaluate relationships between genotype and cognitive/behavioral measures. RESULTS: DRD4 dampened-variants predicted gray matter atrophy in disease-specific regions of FTD in anterior cingulate, ventromedial prefrontal, orbitofrontal and insular cortices on the right greater than the left. Genotype predicted greater apathy and repetitive motor disturbance in patients with FTD. These results covaried with frontoinsular cortical atrophy. Peak atrophy patterned along regions of neuroanatomic vulnerability in FTD-spectrum disorders. In AD subjects and controls, genotype did not impact gray matter intensity. CONCLUSIONS: We conclude that DRD4 polymorphisms with reduced functional potency exacerbate neuronal injury in sites of higher receptor density, which intersect with syndrome-specific regions undergoing neurodegeneration in FTD.


Subject(s)
Brain/pathology , Frontotemporal Dementia/genetics , Frontotemporal Dementia/pathology , Receptors, Dopamine D4/genetics , Receptors, Dopamine D4/physiology , Aged , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Atrophy , Female , Frontotemporal Dementia/psychology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuropsychological Tests , Polymorphism, Genetic , Syndrome
3.
J Biol Chem ; 275(43): 33205-8, 2000 Oct 27.
Article in English | MEDLINE | ID: mdl-10973944

ABSTRACT

Activation of transforming growth factor-beta (TGF-beta) receptors triggers phosphorylation of Smad2 and Smad3. After binding to Smad4, the complex enters the nucleus and interacts with other transcription factors to activate gene transcription. Unlike other Smads, Smad7 inhibits phosphorylation of Smad2 and Smad3, and its transcription is induced by TGF-beta, suggesting a negative feedback loop. Here, we show that TFE3 and Smad3 synergistically mediate TGF-beta-induced transcription from the Smad7 promoter by binding to an E-box and two adjacent Smad binding elements (SBEs), respectively. A precise 3-base pair spacer between one SBE and the E-box is essential. Previously, we showed that a similar arrangement between a SBE and an E-box of an element is essential for TGF-beta-dependent transcription of the plasminogen activator inhibitor-1 gene (PAI-1) and that TGF-beta-induced phosphorylation of Smad3 triggers its association with TFE3. Thus, TFE3-Smad3 response elements may represent a common target for TGF-beta-induced gene expression.


Subject(s)
DNA-Binding Proteins/genetics , DNA-Binding Proteins/pharmacology , Trans-Activators/genetics , Trans-Activators/pharmacology , Transcription Factors/pharmacology , Transcription, Genetic/drug effects , Transforming Growth Factor beta/pharmacology , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Cell Line , DNA-Binding Proteins/metabolism , Drug Synergism , Humans , Promoter Regions, Genetic , Smad3 Protein , Smad7 Protein , Trans-Activators/metabolism , Transcription Factors/metabolism
4.
Proc Natl Acad Sci U S A ; 96(23): 13130-5, 1999 Nov 09.
Article in English | MEDLINE | ID: mdl-10557285

ABSTRACT

Transforming growth factor beta (TGF-beta) regulates a broad range of biological processes, including cell growth, development, differentiation, and immunity. TGF-beta signals through its cell surface receptor serine kinases that phosphorylate Smad2 or Smad3 proteins. Because Smad3 and its partner Smad4 bind to only 4-bp Smad binding elements (SBEs) in DNA, a central question is how specificity of TGF-beta-induced transcription is achieved. We show that Smad3 selectively binds to two of the three SBEs in PE2.1, a TGF-beta-inducible fragment of the plasminogen activator inhibitor-1 promoter, to mediate TGF-beta-induced transcription; moreover, a precise 3-bp spacer between one SBE and the E-box, a binding site for transcription factor muE3 (TFE3), is essential for TGF-beta-induced transcription. Whereas an isolated Smad3 MH1 domain binds to TFE3, TGF-beta receptor-mediated phosphorylation of full-length Smad3 enhances its binding to TFE3. Together, these studies elucidate an important mechanism for specificity in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene.


Subject(s)
DNA-Binding Proteins/metabolism , DNA/metabolism , Plasminogen Activator Inhibitor 1/genetics , Promoter Regions, Genetic , Trans-Activators/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Transforming Growth Factor beta/metabolism , Base Sequence , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Binding Sites , Cell Line , Humans , Phosphorylation , Smad3 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...